Benzothiophene estrogen receptor modulators

A compound selected from:

• or a pharmaceutically acceptable salt thereof,
• wherein A is:
• Y is
• m is 0, 1, or 2;
• n is 1, 2, or 3;
• o is independently 0, 1, 2, 3, 4, or 5;
• Z is selected from —O—, —C(R3)2—, —CHR3—, —CH2—, —CHF—, —CF2—, and —S—;
• ZA and ZB are independently selected from —O—, —C(R3)2—, —CHR3—, —CH2—, —CHF—, —CF2—, and —S—;
• each R1 is independently selected from C1-C3alkyl, halogen, and C1-C3haloalkyl;
• R2 is selected from:
• a. 4-6 membered heterocycle optionally substituted with one, two, or three groups independently selected from R4;
• b. —NH2, —NH(C1-C3alkyl or C2-C3haloalkyl), and —N((independently)C1-C3alkyl or C2-C3haloalkyl)2;
• c. monocyclic 7-8 membered heterocycle optionally substituted with one, two, or three groups independently selected from R4;
• d. 6-12 membered bicyclic or bridged heterocycle optionally substituted with one, two, or three groups independently selected from R4;
• and
• e. hydroxyl, alkoxy, —NH—(CH2)n1—NH2, —NH—(CH2)n1—NH(C1-C12alkyl or C2-C12haloalkyl), —NH—(CH2)n1—N((independently)C1-C12alkyl or C2-C12haloalkyl), —NHC4-C12alkyl, and —N(C1-C12alkyl)2;
• n1 is 2, 3, 4, 5, or 6;
• R3 is independently selected from —F, —Cl, —Br, —CH3, —CH2F, —CHF2, and —CF3;
• R4 is selected from hydrogen, halogen, C1-C3alkyl, and C1-C3haloalkyl;
• or R4 is selected from hydrogen, halogen, C1-C3alkyl, C1-C3haloalkyl, —COOH, —COOC1-C12alkyl, —CONH2, —CON(H)alkyl, and —CON(alkyl)2;
• R5 is selected from hydrogen, halogen, C1-C3alkyl, and C1-C3haloalkyl;
• and
• R7 is a 4, 5, 6, 7, 8, 9, or 10 membered heterocycle optionally substituted with 1, 2, or 3 groups selected from R4.